Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Biochim Biophys Acta. 2015 Jan 20;1850(4):832–844. doi: 10.1016/j.bbagen.2015.01.011

Figure 5. GSK3 inhibition does not affect Nav1.2 total protein levels.

Figure 5

Confocal images of HEK-Nav1.2 showing immunolabeling with a PanNav α subunit antibody (A,B,D,E) and a TOPRO-3 nuclear counterstain (A,D). A and D show a visualization of Nav1.2 channels (red) with the nuclear portions stained (blue) for reference in representative cells treated with DMSO or GSK3 inhibitor XIII, respectively. Single channel images show PanNav intensity (B,E) with 3-dimensional contour plots showing the respective intensity (C, F). Scale bar, 4 μm. G. Summary bar graph representing PanNav pixel intensity in cells treated with GSK3 inhibitor XIII versus control; the two means are not statistically different (p=0.614). H. Western blot analysis of Nav1.2 protein levels from total cell lysate from HEK-Nav1.2 cells treated with either DMSO (left) or GSK3 inhibitor (GSK3i) XIII (right) and probed with a PanNav antibody; calnexin immunoreactivity (rabbit polyclonal antibody) is used as a loading control. The expression levels of Nav1.2 (normalized to calnexin) under GSK3 inhibition were comparable to DMSO control. I. Summary bar graph, treatment did not significantly alter Nav1.2 content in the cells. NS= statistically non-significant.